# QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study

> **NCT06920836** · PHASE2 · COMPLETED · sponsor: **Wuhan Createrna Science and Technology Co., Ltd** · enrollment: 270 (actual)

## Conditions studied

- Cough

## Interventions

- **DRUG:** QR052107B 100 mg
- **DRUG:** QR052107B 400 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06920836
- **Lead sponsor:** Wuhan Createrna Science and Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-21
- **Primary completion:** 2023-11-22
- **Final completion:** 2023-12-25
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920836, "QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06920836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*